Description
Gazyva (obinutuzumab) is a medication used in combination with chemotherapy to treat adults with previously untreated, relapsed, or refractory follicular lymphoma (FL). It is also used with chemotherapy to treat adults with previously untreated chronic lymphocytic leukemia.
Gazyva is given as an intravenous infusion.
Directions
Gazyva is available in 1000 mg/40 mL single-dose vials. The Gazyva package insert should come with the vials. Your healthcare provider will prescribe an appropriate treatment regimen for you. Your healthcare provider may also want you to take medications for infusion-related reactions and tumor lysis syndrome before Gazyva is administered.
Your healthcare provider will administer Gazyva; it will be delivered via an intravenous infusion.
If you have any questions or concerns, consult your healthcare provider.
Ingredients
Obinutuzumab is the active ingredient in Gazyva.
Contraindications
Gazyva should not be administered to patients who have an allergy to the medication, including those who have had serum sickness with previous obinutuzumab use.
Cautions
- Gazyva contains the following FDA Boxed Warning:
- Hepatitis B virus (HBV) reactivation that can result in fulminant hepatitis, liver failure, and death.
- Progressive Multifocal Leukoencephalopathy (PML) that can result in death.
- Before you begin treatment with Gazyva, consult your healthcare provider about:
- All the prescription and nonprescription medications you take
- Your allergies
- Your current health problems and past medical history
- If you are pregnant or breastfeeding
- Infusion-related reactions may occur.
- Serious allergic reactions, including serum sickness, may occur.
- Tumor lysis syndrome may occur.
- Patients with an active infection should not receive Gazyva. Patients may be at an increased risk if they have ever had recurring or chronic infections.
- Decreased platelet counts and neutrophils (a type of white blood cell) may occur.
- Blood clotting problems may occur.
- Live vaccines should not be administered to patients receiving Gazyva and until B-cell recovery.
- Gazyva can cause harm to an unborn baby. Effective birth control methods should be used.
- Women should be advised not to breastfeed while being treated with Gazyva.
Side Effects
Infusion-related reactions, reduced neutrophil count, fatigue, cough, upper respiratory tract infections, musculoskeletal pain, constipation, and diarrhea are some common side effects associated with Gazyva. However, other side effects can occur. Contact your healthcare provider immediately if you are experiencing side effects that bother you or won’t go away.
Ask your healthcare provider about Gazyva.
Reference
Gazyva. South San Francisco, CA: Genentech, Inc.; 2022.
About Dr. Savannah Muncy (Page Author)
Dr. Muncy (PharmD) studied science and education as an undergraduate before attending the Appalachian College of Pharmacy where she completed her PharmD in three years. She is currently using her pharmacy and healthcare expertise to write medical content for clients all around the world. She is focused on delivering the most current, accurate, and engaging information to healthcare professionals and patients. Read More....
IMPORTANT NOTE:
The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.
Product Code : 14388